

COMPOUND FOR PREVENTATIVE TREATMENT OF ALZHEIMER DISEASE

DESCRIPTION OF THE TECHNOLOGY

The Alzheimer Disease (AD) and mild-cognitive impairment (MCI) are unique in their level of unmet clinical and environmental need, as there are no curative therapies, and the rates of diagnosis and treatment are low across all stages of the disease. Since there is a rising prevalence of AD and MCI in the world, there is a public health concern due to the costs associated with healthcare for populations with dementia caused by AD.

As a result of the lack of accurate diagnostic tests, there is a widespread tendency to delay the referral of patients to a neurologist in order to provide earlier access to treatment. However, the pathologic mechanisms, including the accumulation of amyloid plaques in the brain, start up to 25 years before of the first symptoms of the disease. It is known that an effective treatment should be applied in the early phase of the AD. Furthermore, there is a need for early and preventive treatment of the disease.

INCLIVA researchers led by Dr. José Viña have shown the effectiveness of a compound in the treatment of AD and MCI. Such compound has been able to both reduce the number and size of amyloid plaques and improve the cognition using animal models of the disease (APP/PSEN1 transgenic mice).

MARKET APPLICATION SECTORS

Neurology: treatment of Alzheimer disease and mild-cognitive impairment.

TECHNICAL ADVANTAGES AND BUSINESS BENEFITS

The compound:

- is unique for preventive treatment of AD
- treats AD at its early stage
- is no toxic. Its use in humans has been already approved for other indications
- is easy to apply: It can be part of either nutritional or pharmacological interventions.

CURRENT STATE OF DEVELOPMENT

Clinical trial in progress sponsored by INCLIVA
ClinicalTrials.gov Identifier: NCT01982578

INTELLECTUAL PROPERTY RIGHTS

No IP Rights applied yet

COLLABORATION SOUGHT

A Pharma company or investors interested in sponsored a new and more ambitious clinical trial to confirm our previous results.

CONTACT

INCLIVA Innovation Unit
uai@incliva.es